Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Thoracic 2Gastrointestinal 2Dermatologic 2Breast 2Sarcoma 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Melanoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 41Nivolumab 18atezolizumab 8Specimen Handling 7Docetaxel 7durvalumab 6Paclitaxel 6Magnetic Resonance Spectroscopy 6Ipilimumab 6Cyclophosphamide 6Carboplatin 6fludarabine 4avelumab 4Oxaliplatin 4Leucovorin 4Early Intervention, Educational 4Counseling 4Biopsy 4temsirolimus 3spartalizumab 3pazopanib 3olaparib 3lenvatinib 3cabozantinib 3aldesleukin 3Trastuzumab 3Taxes 3Sirolimus 3Psychiatric Rehabilitation 3Fluorouracil 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × ARQ 197 × Gynecologic × Clear all
NCT01178411 2021-03-10

An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1/2 Completed
60 enrolled 11 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡